Skip to main content Skip to section navigation Skip to footer

Inhibikase Therapeutics, Inc.

  • Home
  • About
    • Overview
    • Management Team
    • Board of Directors
    • Science Advisors
  • Technology
    • Overview
    • RAMP™ Drug Innovation Engine
  • Pipeline
    • Overview
    • IkT-148009 for Parkinson’s Disease and GI complications
    • IkT-001Pro for CML
    • IkT-01427 for PML
    • Collaborative Programs
    • Partnering with Inhibikase
  • Scientific Publications
  • Clinical Trials
  • News
    • Press Releases
  • Investors
    • Overview
    • News & Events
    • Company Info
    • Financial Info
    • Stock Data
    • SEC Filings
    • Governance
  • Contact
  • Careers

Press Releases

News

News

  • Press Releases
Jan 05, 2022 8:30am EST

Inhibikase Therapeutics Highlights 2022 Pipeline Goals and Milestones

Nov 29, 2021 8:05am EST

Inhibikase Therapeutics Announces Publication Highlighting Mechanism of Disease and the Potential of Oral c-Abl Kinase Inhibitor Therapy for the Treatment of Parkinson's Disease

Nov 15, 2021 5:30pm EST

Inhibikase Therapeutics Reports Third Quarter 2021 Financial Results and Highlights Recent Period Activity

Oct 27, 2021 8:05am EDT

Inhibikase Therapeutics to Participate in Upcoming Michael J. Fox Foundation Alpha-Synuclein Summit

Oct 19, 2021 8:05am EDT

Inhibikase Therapeutics Announces Dosing of First Parkinson's Patient in its Phase 1b Clinical Trial of IkT-148009

Oct 04, 2021 8:05am EDT

Inhibikase Therapeutics Announces Interim Three-month Results from Chronic Toxicology Studies of its Oral c-Abl Kinase Inhibitor, IkT-148009, in Development for Treatment of Parkinson's Disease

Sep 23, 2021 8:05am EDT

Inhibikase Therapeutics Receives Grant from U.S. National Institutes of Health to Evaluate IkT-148009 for the Treatment of Multiple System Atrophy

Sep 07, 2021 8:00am EDT

Inhibikase Therapeutics to Present at Upcoming H.C. Wainwright 23rd Annual Global Investment Conference

Aug 16, 2021 4:45pm EDT

Inhibikase Therapeutics Reports Second Quarter 2021 Financial Results and Highlights Recent Period Activity

Jul 26, 2021 8:42am EDT

Inhibikase Therapeutics Receives FDA Clearance To Begin Evaluation of IkT-148009 in Parkinson's Patients

  • arrow_back
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • arrow_forward
rss_feed News RSS
  • Visit us on Facebook
  • Visit us on Twitter
  • Visit us on Linkedin
  • Visit us on Youtube
©2023 Inhibikase Therapeutics, Inc. All Rights Reserved.
Privacy Policy Disclaimer Sitemap